MEDITE Cancer Diagnostics, Inc. Newsroom - Profile and News Archive

MEDITE Cancer Diagnostics, Inc. | WithumSmith+Brown P.C., L.J. Soldinger Associates, accounting firms, MEDITE Enterprise Inc

Engage with MEDITE Cancer Diagnostics, Inc.

Learn more online at: http://www.medite-group.com/

Follow: 

RSS News Feed for MEDITE Cancer Diagnostics, Inc.

Press Releases from MEDITE Cancer Diagnostics, Inc. :

MEDITE Cancer Diagnostics, Inc. will present at the SeeThruEquity Healthcare Investor Conference on January 11

MEDITE Cancer Diagnostics

ORLANDO, Fla., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTC:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco.

MEDITE Cancer Diagnostics, Inc. Reports a Profitable Third Quarter and Nine Month 2015 Results

MEDITE Cancer Diagnostics

ORLANDO, Fla., Nov. 17, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT, the ‘Company’ / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.

MEDITE Cancer Diagnostics, Inc. successfully obtained Mexican Tender for 31 Stainers and First Delivery of new Manual Microtome to China

MEDITE Cancer Diagnostics

ORLANDO, Fla., Aug. 27, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc., ( OTCQB:MDIT / OTCMKTS:MDIT ) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining machines with a the total retail value of approximately $600,000. This is the first major sale to Mexico for MEDITE.

MEDITE Cancer Diagnostics, Inc. Reports Second Quarter and Six Month 2015 Results

MEDITE Cancer Diagnostics

ORLANDO, Fla., Aug. 17, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (‘Company,’ OTCQB symbol: MDIT / OTCBB:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results.

MEDITE Cancer Diagnostics, Inc. Announces Change of Auditor

MEDITE Cancer Diagnostics

ORLANDO, Fla., May 14, 2015 (SEND2PRESS NEWSWIRE) — MEDITE Cancer Diagnostics, Inc. (‘Company,’ OTCQB symbol: ‘MDIT’ / OTCBB:MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, announces change of auditors.